Christopher Bunick, MD/PhD
Research & Publications
Biography
News
Research Summary
Dr. Bunick uses structural biology techniques called x-ray crystallography, nuclear magnetic resonance, and cryo-electron microscopy to determine the high resolution, three-dimensional structures of proteins important to both normal and diseased skin. In addition, he uses structural biology to ascertain the biochemical basis for how dermatology drugs work. Knowing the structure of various skin proteins and drug-ligand interactions enables a better understand of how a protein or therapeutic functions in normal and diseased skin states. Ultimately, it may lead to the development of novel, improved therapies or better patient care. In addition to wet-lab/basic science research, Dr. Bunick also leads clinical trial investigations at the Yale Center for Clinical Investigation in order to evaluate cutting-edge therapies and their safety and effectiveness in patients.
Specialized Terms: structural biology of skin proteins; x-ray crystallography; epidermal structure and function; structure-based drug design; cryo-EM; NMR; clinical trial;
Extensive Research Description
Principal Investigator Background
Dr. Christopher Bunick, MD, PhD, is an Associate Professor of Dermatology performing dermatologic research studying the three-dimensional structures of skin-related proteins using primarily x-ray crystallography and cryo-electron microscopy. Dr. Bunick has over 25 years of experience in the field of structural biology. He leads a structural biology research program in the dermatology field, with a specific niche: “atomic resolution dermatology.” Dr. Bunick’s research focuses on determining the atomic resolution structures of proteins, protein complexes, and drug-ligand complexes that are essential to formation of a functional human skin barrier or the action of a precision medicine therapy. He uses x-ray crystallography and cryo-electron microscopy to: 1) determine the high resolution, three-dimensional structures of proteins important to both normal and diseased skin, and 2) determine the mechanism of action of how dermatology drugs bind their molecular target. Knowing the structure of various skin proteins and drugs enables a better understanding of how a protein or therapeutic functions in normal and diseased skin states. Ultimately, it may lead to the development of novel therapies or better patient care.
Areas of Active Basic Science Research
The Bunick lab applies biochemistry, structural biology (X-ray crystallography, Cryo-EM), and cell biology techniques to investigate biological processes of human skin. As a board-certified and practicing dermatologist, Dr. Bunick tackles scientific questions that can improve clinical care of patients. We have ongoing cutting edge translational research in the following areas:
1. Molecular mechanisms of intermediate filament (IF) assembly.
IFs, which include keratins, are fundamental filamentous assemblies that comprise the cellular cytoskeleton, regulate cellular signaling, and form an essential component of the human skin barrier. The Bunick lab discovered a novel assembly mechanism shared among IFs, and we continue to investigate the function of IFs.
2. Molecular mechanisms of human skin barrier integrity.
Keratin IFs regulate the human skin barrier through two key processes: i) filaggrin aggregation of keratins to form an impermeable proteinaceous barrier in the stratum corneum, and ii) keratins bind desmoplakin at desmosomes to enhance cell-cell adhesion in the epidermis. The Bunick lab has determined the only filaggrin structure and 75% of all keratin structures to date, and investigate the mechanisms of keratin assemblies in skin barrier function.
Two recent proteins studied are human profilaggrin and the keratin 1/10 complex because of their importance to skin barrier integrity and association with clinically relevant skin diseases. The NIH/NIAMS website estimates up to 90 million Americans suffer from some form of atopic dermatitis. Atopic dermatitis and other forms of severely dry skin, such as ichthyosis vulgaris, are associated with defects or mutations in profilaggrin and its processed fragment, filaggrin. Similarly, mutations mapped to keratins 1 or 10 are linked to several clinical disorders of keratinization (keratinopathies). Work on these proteins led to a 2.2 Å resolution crystal structure of the profilaggrin S100 calcium-binding domain and several 2.0 Å to 3.3 Å resolution crystal structures of complexes between the 1B and 2B helices of K1 and K10.
3. Acne vulgaris pathogenesis and mechanisms of drug therapy.
Building from our structure of the acne drug sarecycline bound to the 70S ribosome, we investigate how acne drugs function in their pathogenic target, Cutibacterium acnes, and how that impacts clinical efficacy and antibiotic resistance. We investigate how C. acnes regulates the microbiome niche of the pilosebaceous unit.
4. Molecular mechanisms of skin therapeutics in patient care.Dr. Bunick's lab works to understand the biochemical mechanisms of dermatologic drugs. Recent work on the structural mechanism of the acne vulgaris drug sarecycline was published in PNAS, and there are ongoing drug development projects in the lab in acne vulgaris, psoriasis, atopic dermatitis, cancer, and more.
Funding
Dr. Bunick currently is funded by the NIH/NIAMS (R01 Award) and a research grant from Almirall. His laboratory is open to medical students, graduate students, and post-docs motivated by and passionate for applying biochemistry and structural biology to skin disease.
Graduate & Medical Students, Post-docs, and Mentorship
Dr. Bunick's lab is committed to providing a highly intellectual and fun environment to develop the research skills necessary to succeed in life, whether in academia, industry, or elsewhere. We teach students the key processes used in our research, including protein production and purification, biochemical assays, structure determination techniques, and clinical/translational thinking. Dr. Bunick is faculty in the Yale Program in Translational Biomedicine, and participates in the BBS Track: Translational Molecular Medicine, Pharmacology, and Physiology (TMMPP).
Clinical Trials
Dr. Bunick works with the Yale Center for Clinical Investigation to lead clinical trial investigations on promising new dermatology therapeutics. Trials to date include:
Ongoing:
-VAPAUS: A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Pachyonychia Congenita.
-TMB01-301: The ASCEND Study: A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 - with a Parallel Optional Maximal Use Arm - in the Treatment of RXLI (X-linked) or ARCI Ichthyosis in Subjects Aged ≥ 6 Years.
Completed:
-A randomized, parallel, double-blind, vehicle-controlled study to evaluate the safety and efficacy of two different concentrations of topical TMB-001 for the treatment of congenital ichthyosis.
-A randomized, bilateral comparison, vehicle-controlled, safety and tolerability study of topical PAT-001 for the treatment of congenital ichthyosis.
Coauthors
Research Interests
Biochemistry; Biophysics; Dermatitis, Atopic; Dermatology; Epidermis; Intermediate Filaments; Keratins; Molecular Biology; Skin; Ichthyosis Vulgaris; Crystallography, X-Ray; Computational Biology; Proteomics
Public Health Interests
Cancer
Research Images
Selected Publications
- Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL StudyMarathe K, Teng J, Guenthner S, Bunick C, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study Dermatology And Therapy 2023, 13: 1255-1264. PMID: 37170057, PMCID: PMC10264299, DOI: 10.1007/s13555-023-00923-1.
- 1041 Atomic resolution structure of the cutibacterium acnes ribosome reveals the mechanism of protein synthesis inhibition by the antibiotic sarecyclineLomakin I, Devarkar S, Patel S, Grada A, Bunick C. 1041 Atomic resolution structure of the cutibacterium acnes ribosome reveals the mechanism of protein synthesis inhibition by the antibiotic sarecycline Journal Of Investigative Dermatology 2023, 143: s178. DOI: 10.1016/j.jid.2023.03.1052.
- 1130 Clinically relevant differences in the chemical and structural mechanism of action of dermatological phosphodiesterase-4 inhibitorsWang J, Bunick C. 1130 Clinically relevant differences in the chemical and structural mechanism of action of dermatological phosphodiesterase-4 inhibitors Journal Of Investigative Dermatology 2023, 143: s194. DOI: 10.1016/j.jid.2023.03.1142.
- 831 The skin microbiome and inflammation of Southeast Asian patients with cutaneous ichthyosisBui B, Ho M, Bunick C. 831 The skin microbiome and inflammation of Southeast Asian patients with cutaneous ichthyosis Journal Of Investigative Dermatology 2023, 143: s143. DOI: 10.1016/j.jid.2023.03.841.
- 1097 The structure of IL-23 inhibitor epitopes correlates with short-term clinical efficacy in plaque psoriasisDaniele S, Eldirany S, Bunick C. 1097 The structure of IL-23 inhibitor epitopes correlates with short-term clinical efficacy in plaque psoriasis Journal Of Investigative Dermatology 2023, 143: s188. DOI: 10.1016/j.jid.2023.03.1109.
- Demystifying Hand EczemaGrada A, Bunick C. Demystifying Hand Eczema Journal Of Investigative Dermatology 2023 PMID: 37115112, DOI: 10.1016/j.jid.2023.03.1666.
- Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: Results from the Phase 2b CONTROL study.Bunick C, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: Results from the Phase 2b CONTROL study. Clinical And Experimental Dermatology 2023 PMID: 36928932, DOI: 10.1093/ced/llad105.
- Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanismLomakin I, Devarkar S, Patel S, Grada A, Bunick C. Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism Nucleic Acids Research 2023, 51: 2915-2930. PMID: 36864821, PMCID: PMC10085706, DOI: 10.1093/nar/gkad103.
- Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis.Murrell D, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Bunick C. Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis. Clinical And Experimental Dermatology 2023, 48: 623-630. PMID: 36794376, DOI: 10.1093/ced/llad033.
- Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016.Grada A, Armstrong A, Bunick C, Salem R, Feldman S. Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016. Journal Of Drugs In Dermatology 2023, 22: 265-270. PMID: 36877883, DOI: 10.36849/jdd.7345.
- Inguinal patch in mpox (monkeypox) virus infection and eccrine syringometaplasia: report of two cases with in situ hybridization and electron microscopy findings.Roy S, Sarhan J, Liu X, Murphy M, Bunick C, Choate K, Damsky W, McNiff J. Inguinal patch in mpox (monkeypox) virus infection and eccrine syringometaplasia: report of two cases with in situ hybridization and electron microscopy findings. British Journal Of Dermatology 2022, 188: 574-576. PMID: 36763786, DOI: 10.1093/bjd/ljac146.
- Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient ManagementDaniele S, Kim S, Grada A, Moore A, Suozzi K, Bunick C. Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management American Journal Of Clinical Dermatology 2022, 24: 199-223. PMID: 36539678, DOI: 10.1007/s40257-022-00746-4.
- Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicityGrada A, Del Rosso J, Moore A, Gold L, Harper J, Damiani G, Shaw K, Obagi S, Salem R, Tanaka S, Bunick C. Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity Frontiers In Medicine 2022, 9: 1033980. PMID: 36569144, PMCID: PMC9773825, DOI: 10.3389/fmed.2022.1033980.
- Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the LiteratureBelzer A, Weiss E, Etaee F, Bunick CG, Damsky W, Nelson CA. Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature Antibiotics 2022, 11: 1398. PMID: 36290055, PMCID: PMC9598652, DOI: 10.3390/antibiotics11101398.
- Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne VulgarisSwallow MA, Fan R, Cohen JM, Bunick CG. Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris Antibiotics 2022, 11: 1032. PMID: 36009899, PMCID: PMC9405006, DOI: 10.3390/antibiotics11081032.
- The CONTROL study: A randomized, double-blind vehicle-controlled Phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosisTeng JMC, Bunick CG, Guenthner S, Murrell DF, Marathe K, Kempers S, Eads K, Mendelsohn AM, Raiz J, Tavakkol A, Castelo-Soccio L. The CONTROL study: A randomized, double-blind vehicle-controlled Phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis Journal Of The American Academy Of Dermatology 2022, 87: 1455-1458. PMID: 35872261, DOI: 10.1016/j.jaad.2022.07.028.
- Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in DermatologyGrada A, Ghannoum MA, Bunick CG. Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology Antibiotics 2022, 11: 722. PMID: 35740129, PMCID: PMC9220064, DOI: 10.3390/antibiotics11060722.
- Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a Phase 2a proof-of-concept studyPaller AS, Browning J, Parish LC, Bunick CG, Rome Z, Bhatia N. Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a Phase 2a proof-of-concept study Journal Of The American Academy Of Dermatology 2022, 87: 1189-1191. PMID: 35271936, DOI: 10.1016/j.jaad.2022.02.060.
- Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal MicrobiotaGhannoum MA, Long L, Bunick CG, Del Rosso JQ, Gamal A, Tyring SK, McCormick TS, Grada A. Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota Antibiotics 2022, 11: 324. PMID: 35326788, PMCID: PMC8944611, DOI: 10.3390/antibiotics11030324.
- Update of the keratin gene family: evolution, tissue-specific expression patterns, and relevance to clinical disordersHo M, Thompson B, Fisk JN, Nebert DW, Bruford EA, Vasiliou V, Bunick CG. Update of the keratin gene family: evolution, tissue-specific expression patterns, and relevance to clinical disorders Human Genomics 2022, 16: 1. PMID: 34991727, PMCID: PMC8733776, DOI: 10.1186/s40246-021-00374-9.
- Sarecycline treatment for acne vulgaris: Rationale for weight‐based dosing and limited impact of food intake on clinical efficacyGrada A, Del Rosso JQ, Graber E, Bunick CG, Gold L, Moore AY, Baldwin H, Obagi Z, Damiani G, Carrothers T, McNamee B, Hanze E. Sarecycline treatment for acne vulgaris: Rationale for weight‐based dosing and limited impact of food intake on clinical efficacy Dermatologic Therapy 2021, 35: e15275. PMID: 34923732, PMCID: PMC9286649, DOI: 10.1111/dth.15275.
- Keratin 1 as a cell-surface receptor in cancerOgunnigbagbe O, Bunick CG, Kaur K. Keratin 1 as a cell-surface receptor in cancer Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer 2021, 1877: 188664. PMID: 34890750, PMCID: PMC8818032, DOI: 10.1016/j.bbcan.2021.188664.
- Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia CongenitaWu TT, Eldirany SA, Bunick CG, Teng JMC. Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia Congenita Journal Of Investigative Dermatology 2021, 141: 2876-2884.e4. PMID: 34116063, PMCID: PMC8922998, DOI: 10.1016/j.jid.2021.03.035.
- 199 Activity of sarecycline in murine models of infection and inflammationBunick C, Del Rosso J, Tyring S, Draper M, Johnson J, Grada A. 199 Activity of sarecycline in murine models of infection and inflammation Journal Of Investigative Dermatology 2021, 141: s36. DOI: 10.1016/j.jid.2021.02.220.
- Dermatomyositis Associated with an Adrenal AdenomaEldirany SA, Ring N, Laskin W, Bunick CG. Dermatomyositis Associated with an Adrenal Adenoma JAAD Case Reports 2021, 12: 70-73. PMID: 34041336, PMCID: PMC8141419, DOI: 10.1016/j.jdcr.2021.04.012.
- Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and InflammationBunick CG, Keri J, Tanaka SK, Furey N, Damiani G, Johnson JL, Grada A. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation Antibiotics 2021, 10: 439. PMID: 33920812, PMCID: PMC8071131, DOI: 10.3390/antibiotics10040439.
- Spectrum of Antibiotic Activity and Its Relevance to the MicrobiomeGrada A, Bunick CG. Spectrum of Antibiotic Activity and Its Relevance to the Microbiome JAMA Network Open 2021, 4: e215357. PMID: 33914053, DOI: 10.1001/jamanetworkopen.2021.5357.
- Sarecycline Demonstrates Narrow spectrum Antibacterial Activity and Anti inflammatory Effect in Animal ModelsBunick C, Del Rosso J, Tyring S, Draper M, Johnson J, Grada A. Sarecycline Demonstrates Narrow spectrum Antibacterial Activity and Anti inflammatory Effect in Animal Models SKIN The Journal Of Cutaneous Medicine 2021, 5: s14. DOI: 10.25251/skin.5.supp.14.
- Recent insight into intermediate filament structureEldirany SA, Lomakin IB, Ho M, Bunick CG. Recent insight into intermediate filament structure Current Opinion In Cell Biology 2020, 68: 132-143. PMID: 33190098, PMCID: PMC7925366, DOI: 10.1016/j.ceb.2020.10.001.
- Patient and Physician Perspectives on Teledermatology at an Academic Dermatology Department amid the COVID-19 PandemicAsabor EN, Bunick CG, Cohen JM, Perkins SH. Patient and Physician Perspectives on Teledermatology at an Academic Dermatology Department amid the COVID-19 Pandemic Journal Of The American Academy Of Dermatology 2020, 84: 158-161. PMID: 32946971, PMCID: PMC7491373, DOI: 10.1016/j.jaad.2020.09.029.
- Molecular Modeling of Pathogenic Mutations in the Keratin 1B DomainHinbest AJ, Eldirany SA, Ho M, Bunick CG. Molecular Modeling of Pathogenic Mutations in the Keratin 1B Domain International Journal Of Molecular Sciences 2020, 21: 6641. PMID: 32927888, PMCID: PMC7555247, DOI: 10.3390/ijms21186641.
- Structural properties of target binding by profilaggrin A and B domains and other S100 fused-type calcium-binding proteinsHinbest AJ, Kim SR, Eldirany SA, Lomakin IB, Watson J, Ho M, Bunick CG. Structural properties of target binding by profilaggrin A and B domains and other S100 fused-type calcium-binding proteins Journal Of Dermatological Science 2020, 100: 39-49. PMID: 32893105, PMCID: PMC7752840, DOI: 10.1016/j.jdermsci.2020.08.009.
- Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosomeBatool Z, Lomakin IB, Polikanov YS, Bunick CG. Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 20530-20537. PMID: 32817463, PMCID: PMC7456112, DOI: 10.1073/pnas.2008671117.
- 576 Crystal structure of sarecycline bound to the 70S bacterial ribosome reveals structural differences from other tetracyclines at atomic resolutionBatool Z, Lomakin I, Polikanov Y, Bunick C. 576 Crystal structure of sarecycline bound to the 70S bacterial ribosome reveals structural differences from other tetracyclines at atomic resolution Journal Of Investigative Dermatology 2020, 140: s79. DOI: 10.1016/j.jid.2020.03.586.
- The New Normal: An approach to optimizing and combining in-person and telemedicine visits to maximize patient careCohen JM, Bunick CG, Perkins SH. The New Normal: An approach to optimizing and combining in-person and telemedicine visits to maximize patient care Journal Of The American Academy Of Dermatology 2020, 83: e361-e362. PMID: 32593636, PMCID: PMC7316470, DOI: 10.1016/j.jaad.2020.06.075.
- CD8+ mycosis fungoides palmaris et plantaris with peripheral blood involvementYumeen S, Mirza FN, Lewis JM, Carlson KR, King B, Cowper S, Bunick CG, McNiff J, Girardi M. CD8+ mycosis fungoides palmaris et plantaris with peripheral blood involvement JAAD Case Reports 2020, 6: 434-437. PMID: 32382639, PMCID: PMC7200192, DOI: 10.1016/j.jdcr.2020.02.025.
- Teledermatology in the Era of COVID-19: Experience of an Academic Department of DermatologyPerkins S, Cohen JM, Nelson CA, Bunick CG. Teledermatology in the Era of COVID-19: Experience of an Academic Department of Dermatology Journal Of The American Academy Of Dermatology 2020, 83: e43-e44. PMID: 32305442, PMCID: PMC7162755, DOI: 10.1016/j.jaad.2020.04.048.
- Crystal Structure of Keratin 1/10(C401A) 2B Heterodimer Demonstrates a Proclivity for the C-Terminus of Helix 2B to Form Higher Order Molecular Contacts.Lomakin IB, Hinbest AJ, Ho M, Eldirany SA, Bunick CG. Crystal Structure of Keratin 1/10(C401A) 2B Heterodimer Demonstrates a Proclivity for the C-Terminus of Helix 2B to Form Higher Order Molecular Contacts. The Yale Journal Of Biology And Medicine 2020, 93: 3-17. PMID: 32226330, PMCID: PMC7087056.
- Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy.Eldirany SA, Ho M, Bunick CG. Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy. The Yale Journal Of Biology And Medicine 2020, 93: 19-27. PMID: 32226331, PMCID: PMC7087057.
- The Interface between Keratin Structurotype and Human DiseaseEldirany SA, Ho M, Bunick CG. The Interface between Keratin Structurotype and Human Disease Structure 2020, 28: 271-273. PMID: 32130887, PMCID: PMC7252399, DOI: 10.1016/j.str.2020.02.002.
- Ixekizumab-induced alopecia areataEldirany SA, Myung P, Bunick CG. Ixekizumab-induced alopecia areata JAAD Case Reports 2019, 6: 51-53. PMID: 31909139, PMCID: PMC6938813, DOI: 10.1016/j.jdcr.2019.10.012.
- Successful management of malodor from fungating tumors using crushed metronidazole tabletsHu JK, Ligtenberg KG, Leventhal J, Bunick CG. Successful management of malodor from fungating tumors using crushed metronidazole tablets JAAD Case Reports 2019, 6: 26-29. PMID: 31909133, PMCID: PMC6938872, DOI: 10.1016/j.jdcr.2019.10.025.
- Alterations in connexin 26 protein structure from lethal keratitis-ichthyosis-deafness syndrome mutations A88V and G45ELilly E, Strickler M, Milstone LM, Bunick CG. Alterations in connexin 26 protein structure from lethal keratitis-ichthyosis-deafness syndrome mutations A88V and G45E Journal Of Dermatological Science 2019, 95: 119-122. PMID: 31331740, PMCID: PMC7263394, DOI: 10.1016/j.jdermsci.2019.07.002.
- 339 Keratin 1–keratin 10 helix 1B tetramer crystal structures reveal a knob-pocket mechanism important for proper assembly of intermediate filamentsHinbest A, Ho M, Eldirany S, Lomakin I, Bunick C. 339 Keratin 1–keratin 10 helix 1B tetramer crystal structures reveal a knob-pocket mechanism important for proper assembly of intermediate filaments Journal Of Investigative Dermatology 2019, 139: s58. DOI: 10.1016/j.jid.2019.03.415.
- Human keratin 1/10‐1B tetramer structures reveal a knob‐pocket mechanism in intermediate filament assemblyEldirany SA, Ho M, Hinbest AJ, Lomakin IB, Bunick CG. Human keratin 1/10‐1B tetramer structures reveal a knob‐pocket mechanism in intermediate filament assembly The EMBO Journal 2019, 38 PMID: 31036554, PMCID: PMC6545558, DOI: 10.15252/embj.2018100741.
- More than keratitis, ichthyosis, and deafness: Multisystem effects of lethal GJB2 mutationsLilly E, Bunick CG, Maley AM, Zhang S, Spraker MK, Theos AJ, Vivar KL, Seminario-Vidal L, Bennett AE, Sidbury R, Ogawa Y, Akiyama M, Binder B, Hadj-Rabia S, Morotti RA, Glusac EJ, Choate KA, Richard G, Milstone LM. More than keratitis, ichthyosis, and deafness: Multisystem effects of lethal GJB2 mutations Journal Of The American Academy Of Dermatology 2018, 80: 617-625. PMID: 30287322, PMCID: PMC6372339, DOI: 10.1016/j.jaad.2018.09.042.
- 689 The x-ray crystal structure of human keratin 1 with S233L mutation demonstrates mechanism of pathogenic tonotubular keratin formation leading to epidermolytic palmoplantar keratodermaEldirany S, Hinbest A, Lomakin I, Bunick C. 689 The x-ray crystal structure of human keratin 1 with S233L mutation demonstrates mechanism of pathogenic tonotubular keratin formation leading to epidermolytic palmoplantar keratoderma Journal Of Investigative Dermatology 2018, 138: s117. DOI: 10.1016/j.jid.2018.03.698.
- 713 The crystal structure of keratin 1/10(Cys401Ala) helix 2B heterodimer determined at 2.0 Å resolutionLomakin I, Hinbest A, Bunick C. 713 The crystal structure of keratin 1/10(Cys401Ala) helix 2B heterodimer determined at 2.0 Å resolution Journal Of Investigative Dermatology 2018, 138: s121. DOI: 10.1016/j.jid.2018.03.722.
- 452 Alterations to connexin 26 protein structure caused by the lethal keratitis-ichthyosis-deafness syndrome mutations A88V and G45EBunick C, Lilly E, Milstone L. 452 Alterations to connexin 26 protein structure caused by the lethal keratitis-ichthyosis-deafness syndrome mutations A88V and G45E Journal Of Investigative Dermatology 2017, 137: s78. DOI: 10.1016/j.jid.2017.02.471.
- The X-Ray Crystal Structure of the Keratin 1-Keratin 10 Helix 2B Heterodimer Reveals Molecular Surface Properties and Biochemical Insights into Human Skin DiseaseBunick CG, Milstone LM. The X-Ray Crystal Structure of the Keratin 1-Keratin 10 Helix 2B Heterodimer Reveals Molecular Surface Properties and Biochemical Insights into Human Skin Disease Journal Of Investigative Dermatology 2016, 137: 142-150. PMID: 27595935, PMCID: PMC5514376, DOI: 10.1016/j.jid.2016.08.018.
- Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapySuozzi KC, Stahl M, Ko CJ, Chiang A, Gettinger SN, Siegel MD, Bunick CG. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy JAAD Case Reports 2016, 2: 264-268. PMID: 27486590, PMCID: PMC4949498, DOI: 10.1016/j.jdcr.2016.05.002.
- 342 Characterization of the molecular surface properties of keratin 1–keratin 10 intermediate filaments using x-ray crystallographyMilstone L, Bunick C. 342 Characterization of the molecular surface properties of keratin 1–keratin 10 intermediate filaments using x-ray crystallography Journal Of Investigative Dermatology 2016, 136: s60. DOI: 10.1016/j.jid.2016.02.374.
- 376 The x-ray crystal structure of a keratin 1–keratin 10 heterocomplex demonstrates how patient mutations disrupt protein chemistry to cause human keratinopathiesBunick C. 376 The x-ray crystal structure of a keratin 1–keratin 10 heterocomplex demonstrates how patient mutations disrupt protein chemistry to cause human keratinopathies Journal Of Investigative Dermatology 2016, 136: s67. DOI: 10.1016/j.jid.2016.02.409.
- Genomic landscape of cutaneous T cell lymphomaChoi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic landscape of cutaneous T cell lymphoma Nature Genetics 2015, 47: 1011-1019. PMID: 26192916, PMCID: PMC4552614, DOI: 10.1038/ng.3356.
- Crystal Structure of Human Profilaggrin S100 Domain and Identification of Target Proteins Annexin II, Stratifin, and HSP27Bunick CG, Presland RB, Lawrence OT, Pearton DJ, Milstone LM, Steitz TA. Crystal Structure of Human Profilaggrin S100 Domain and Identification of Target Proteins Annexin II, Stratifin, and HSP27 Journal Of Investigative Dermatology 2015, 135: 1801-1809. PMID: 25760235, PMCID: PMC4466033, DOI: 10.1038/jid.2015.102.
- Perspectives on Physiology and Medicine from Nobel Prize Winners: The 64th Lindau Nobel Laureate MeetingBunick CG. Perspectives on Physiology and Medicine from Nobel Prize Winners: The 64th Lindau Nobel Laureate Meeting Journal Of Investigative Dermatology 2014, 134: 2853-2855. PMID: 25381760, DOI: 10.1038/jid.2014.358.
- Biochemical and Structural Domain Analysis of Xeroderma Pigmentosum Complementation Group C Protein †Bunick CG, Miller MR, Fuller BE, Fanning E, Chazin WJ. Biochemical and Structural Domain Analysis of Xeroderma Pigmentosum Complementation Group C Protein † Biochemistry 2006, 45: 14965-14979. PMID: 17154534, PMCID: PMC2579963, DOI: 10.1021/bi061370o.
- Use of an open‐flow helium cryostat for macromolecular cryocrystallographyHanson B, Martin A, Harp J, Parrish D, Bunick C, Kirschbaum K, Pinkerton A, Bunick G. Use of an open‐flow helium cryostat for macromolecular cryocrystallography Journal Of Applied Crystallography 1999, 32: 814-820. DOI: 10.1107/s0021889899005026.
Clinical Trials
Conditions | Study Title |
---|---|
Diseases of the Integumentary System; Genetics - Adult; Genetics - Pediatric | The ASCEND Study |